CA1049409A - Preparation of steroid-neomycin topical composition - Google Patents
Preparation of steroid-neomycin topical compositionInfo
- Publication number
- CA1049409A CA1049409A CA224,302A CA224302A CA1049409A CA 1049409 A CA1049409 A CA 1049409A CA 224302 A CA224302 A CA 224302A CA 1049409 A CA1049409 A CA 1049409A
- Authority
- CA
- Canada
- Prior art keywords
- weight
- neomycin
- steroid
- betamethasone
- benzoate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 229960004927 neomycin Drugs 0.000 title claims abstract description 25
- 230000000699 topical effect Effects 0.000 title claims description 7
- 229930193140 Neomycin Natural products 0.000 claims abstract description 24
- 150000003431 steroids Chemical class 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 239000000243 solution Substances 0.000 claims abstract description 9
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000007864 aqueous solution Substances 0.000 claims abstract description 5
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 14
- SOQJPQZCPBDOMF-YCUXZELOSA-N betamethasone benzoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@@H]1C)C(=O)CO)C(=O)C1=CC=CC=C1 SOQJPQZCPBDOMF-YCUXZELOSA-N 0.000 claims description 14
- 229960000870 betamethasone benzoate Drugs 0.000 claims description 14
- 229940053050 neomycin sulfate Drugs 0.000 claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 11
- 235000019441 ethanol Nutrition 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 239000004615 ingredient Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 229920005862 polyol Polymers 0.000 claims description 5
- 150000003077 polyols Chemical class 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical group N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims 5
- 239000000499 gel Substances 0.000 description 9
- OIXVKQDWLFHVGR-WQDIDPJDSA-N neomycin B sulfate Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO OIXVKQDWLFHVGR-WQDIDPJDSA-N 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 206010033546 Pallor Diseases 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- UUOUOERPONYGOS-CLCRDYEYSA-N Fluocinolone Chemical group O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 UUOUOERPONYGOS-CLCRDYEYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910001510 metal chloride Inorganic materials 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
- 239000003351 stiffener Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46025474A | 1974-04-11 | 1974-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1049409A true CA1049409A (en) | 1979-02-27 |
Family
ID=23827960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA224,302A Expired CA1049409A (en) | 1974-04-11 | 1975-04-10 | Preparation of steroid-neomycin topical composition |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPS535729B2 (cs) |
| AU (1) | AU7776275A (cs) |
| CA (1) | CA1049409A (cs) |
| DE (2) | DE2504615C3 (cs) |
| DK (1) | DK143537C (cs) |
| FR (1) | FR2267107B1 (cs) |
| GB (1) | GB1455552A (cs) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1984000111A1 (en) * | 1982-06-24 | 1984-01-19 | Robert Alan Smith | Pharmaceutical gel composition |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4489070A (en) * | 1983-05-13 | 1984-12-18 | Schering Corporation | Betamethasone dipropionate cream |
| DE3333240A1 (de) * | 1983-09-12 | 1985-03-28 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mittel zur transdermalen applikation von arzneimittelwirkstoffen |
| AU592065B2 (en) * | 1984-10-09 | 1990-01-04 | Dow Chemical Company, The | Sustained release dosage form based on highly plasticized cellulose ether gels |
| FR2588189B1 (fr) * | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| DE3614095A1 (de) * | 1986-04-25 | 1987-10-29 | Goedecke Ag | Oxyalkylcellulose enthaltende gelzubereitung |
| ES2078256T3 (es) * | 1990-04-05 | 1995-12-16 | Knoll Ag | Formula farmaceutica para uso topico que contiene diclofenaco sodico. |
| AU2000268609A1 (en) * | 2000-09-14 | 2002-03-26 | Robert Theiler | Intraarticular agent for the treatment of osteoarthritis |
| DK2366408T3 (da) * | 2010-03-01 | 2012-10-22 | Salvat Lab Sa | Vandige, klare opløsninger af fluocinolonacetonid til behandling af inflammation i øret |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1017746B (de) * | 1954-02-09 | 1957-10-17 | Upjohn Co | Verfahren zur Herstellung frei fliessender, nicht absetzender therapeutisch wirksamer Suspensionen |
| US3485915A (en) * | 1966-04-22 | 1969-12-23 | Revlon | Thickened hydroxypropyl cellulose compositions |
| DE2015300A1 (de) * | 1969-04-01 | 1970-10-29 | Syntex Corp., Panania;PM | örtliche, entzündungshemmende Präparate und Verfahren zu ihrer Verwendung |
| DK135267A (cs) * | 1971-02-25 |
-
1975
- 1975-01-30 AU AU77762/75A patent/AU7776275A/en not_active Expired
- 1975-02-04 DE DE19752504615 patent/DE2504615C3/de not_active Expired
- 1975-03-20 JP JP3426675A patent/JPS535729B2/ja not_active Expired
- 1975-03-21 GB GB955575A patent/GB1455552A/en not_active Expired
- 1975-04-07 DK DK147575A patent/DK143537C/da not_active IP Right Cessation
- 1975-04-07 FR FR7510763A patent/FR2267107B1/fr not_active Expired
- 1975-04-10 CA CA224,302A patent/CA1049409A/en not_active Expired
- 1975-04-10 DE DE19752515594 patent/DE2515594C3/de not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1984000111A1 (en) * | 1982-06-24 | 1984-01-19 | Robert Alan Smith | Pharmaceutical gel composition |
Also Published As
| Publication number | Publication date |
|---|---|
| DE2515594B2 (de) | 1978-12-07 |
| DE2515594C3 (de) | 1982-06-03 |
| AU7776275A (en) | 1976-08-05 |
| DE2504615A1 (de) | 1975-10-16 |
| DK143537C (da) | 1982-02-01 |
| FR2267107A1 (cs) | 1975-11-07 |
| DE2515594A1 (de) | 1975-10-30 |
| DK147575A (cs) | 1975-10-12 |
| GB1455552A (en) | 1976-11-17 |
| JPS535729B2 (cs) | 1978-03-01 |
| DE2504615B2 (de) | 1977-07-14 |
| DK143537B (da) | 1981-09-07 |
| DE2504615C3 (de) | 1980-10-02 |
| FR2267107B1 (cs) | 1978-07-28 |
| JPS50132122A (cs) | 1975-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0362270B2 (en) | Steroid lotion | |
| US8232304B2 (en) | Antifungal formulations | |
| US5110809A (en) | Antifungal gel formulations | |
| US5002938A (en) | Antifungal gel formulations | |
| US5414011A (en) | Preservative system for ophthalmic formulations | |
| US4607038A (en) | Ophthalmic pranoprofen compositions | |
| US4323558A (en) | Topical trien containing pharmaceutical compositions and methods of use | |
| EP2420223B1 (en) | Aqueous pharmaceutical compositions containing borate-polyol complexes | |
| US4873265A (en) | Anti-infective methods and compositions | |
| US4013792A (en) | Process for the production of base for topical steroids | |
| US20120028942A1 (en) | Medicinal Cream Made Using Neomycin Sulphate, Betamethasone Valerate, And Chitosan, And A Process To Make The Same | |
| CA1049409A (en) | Preparation of steroid-neomycin topical composition | |
| EP0988040B1 (en) | Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain | |
| JP2997202B2 (ja) | 局所的眼科用途の為のトブラマイシンとステロイドの組合わせ | |
| US4929619A (en) | Anti-infective methods and compositions | |
| CA2053721A1 (en) | Antiphlogistic analgesic cream composition | |
| RU2223097C1 (ru) | Комбинированное средство для лечения кожных заболеваний | |
| US4897404A (en) | Anti-infective methods and compositions | |
| NZ235054A (en) | Gel formulation comprising imidazole antifungal agent and a 17-ester steroid anti-inflammatory agent with a co-solvent system and a gelling agent | |
| US5879711A (en) | Stable antiandrogenic gel composition | |
| US4895857A (en) | Anti-infective methods and compositions | |
| US4895859A (en) | Anti-infective methods and compositions | |
| WO2003097070A1 (en) | The pharmaceutical composition comprising a corticosteroid and an antiseptic | |
| CA1319105C (en) | Antifungal gel formulations | |
| RU2398587C2 (ru) | Композиция |